MyBiotics Pharma Overview
MyBiotics Pharma is a microbiome company focused on bettering peoples lives and health by greatly improving on existing probiotic solutions. MyBiotics has developed a novel technological platform for the development of microbiome-related drugs and supplements. The companys platform uses innovative formulation, delivery, and culturing methods designed to provide better viability and resistance, and potentially improved colonization and clinical results. Based on this proprietary innovation, MyBiotics has developed three main technologies: MyCrobe, SuperDonor, and Super Donor Select, which are all supported by MyLiveIn, a computational and AI technology platform. After targeting specific medical indications, MyBiotics has now reached the clinical stage with three products. Based on the companys SuperDonor technology, its MBX-SD-201 and MBX-SD-202 products offer safe and reproducible microbiome restoration and may become an alternative for complete microbiome recovery and design using fecal microbiota transplantation. MyBiotics has initiated significant collaborations and development agreements with a variety of pharmaceutical companies and clinical partners in the areas of C. diff, oncology, dermatology, and womens health.
Cumulative Funding Raised Over Time ($)
$8.0MAug 2018
$8.0MFeb 2021
$8.7MMar 2016
$9.0MMay 2015
Latest News
growth-positive
MyBiotics announces successful completion of the Phase I trial for its MBX-SD-202 whole microbiome treatment, driving an innovative path to new restoration therapies using microbiome culturing technology
MyBiotics Pharma Ltd has successfully completed Phase I clinical trial of MBX-SD-202, a whole microbiome treatment for recurrent and severe cases of Clostridioides difficile infection. The trial confirmed the safety of MBX-SD-202 in healthy volunteers and supports further development of the companys SuperDonor™ technology. MyBiotics plans to continue clinical development of MBX-SD-202 for recurrent C. diff and related medical indications. The SuperDonor™ technology has the potential to be applied to multiple indications, such as oncology, in the companys clinical pipeline. MyBiotics is a clinical stage company focused on microbiome-based products for the biopharmaceutical and supplement markets.
Customers
growth-positive
MyBiotics, Hadassah to study impact of microbiome on cancer therapies
MyBiotics Pharma Ltd. is partnering with Hadasit Medical Research Services and Development Ltd., the technology transfer arm of Hadassah Medical Center, to develop microbiome-based therapies to improve cancer immunotherapies for melanoma patients. MyBiotics has developed technologies to culture, ferment, and deliver stable and diverse bacterial communities that can target different sites across the human body to restore the microbiome equilibrium. The collaboration will combine Hadassah’s expertise in immunotherapy treatment for melanoma patients with MyBiotics’ microbiome technologies.
Partners
growth-positive
Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health BioSpace
Ferring Pharmaceuticals, Rebiotix Inc., and MyBiotics Pharma Ltd. have announced a strategic collaboration to develop live microbiota-based biotherapeutics for bacterial vaginosis. The collaboration aims to reduce the need for antibiotics and provide a long-term treatment solution for the common vaginal infection. The agreement combines MyBiotics culturing and delivery technologies with Rebiotixs expertise in developing clinical-stage microbiota-based products and Ferrings therapeutic development and commercial expertise. The collaboration is an important step forward in harnessing the power of the human microbiome in womens health. The partnership between Ferring and MyBiotics builds on their existing collaboration initiated in 2017. The collaboration also adds several firsts to Ferrings microbiome product pipeline, including the companys first non-donor derived formulation and a live microbiota-based product specific to reproductive medicine.
Partners
growth-positive
MyBiotics Pharma Receives Investment from Mii Fund, an Innovator in the Field of Dermatology
MyBiotics Pharma has received an investment from Mii Fund, a partnership with Maruho Co. Ltd., to advance its microbiome therapeutics pipeline and enhance its microbiome platform technologies. The company is also initiating a development program in the field of skin microbiome. MyBiotics has developed breakthrough technologies for generating a stable and diverse bacterial community. The investment will strengthen the companys technology platforms and accelerate the development of its microbiome-based pipeline.
InvestmentPartners
growth-positive
Galmed and MyBiotics to Collaborate in Development of Bespoke Microbiome Signature for Aramchol
Galmed Pharmaceuticals and MyBiotics Pharma have entered into a research and development collaboration agreement to identify and optimize the selected microbiome repertoire associated with the response to Aramchol. The collaboration aims to develop a standalone microbiome-based treatment for non-alcoholic steatohepatitis (NASH) and fibrosis. MyBiotics will use its proprietary SuperDonor technology to identify and optimize consortia of bacteria to enhance Aramchols clinical efficacy and response rate. The collaboration also aims to identify specific microbial biomarkers for Aramchol based on macrobiome data collected from Galmeds clinical studies. The partnership is part of Galmeds plan to maximize Aramchols clinical efficacy and leverage the growing interest in the microbiome as a novel drug modality.
Partners
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $11.27M |
| Last funding | Undisclosed |
| Stage | A |
| Rounds | 5 |
| Investors | 1 |
Team Members
4
Employees: 11-50
Web & Social Links
| Website | mybiotics-pharma.com/ |
| Careers | Careers page |
Locations
Yitzhak Modai St 2, Rehovot, Israel
Photos & Videos
1 item(s)
MyBiotics Pharma Business
Business models
B2B, B2C
Product stage
Clinical Trial
Employees
11-50
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryDrugs Discovery & DevelopmentBiomaterials & Tissue EngineeringTarget Customer
Healthcare & Life SciencesHealthcarePatientsLife SciencesPharmaceuticalsConsumersRecreational & LifestyleFitness & SportsCore Technology
BiologicalsMicroorganismsTags (24)
bacteriasupplementsgastroenterologydrug-deliveryoncologycancermicrobiomepharmaceuticalspharma-companiescosmeticsdermatologynutritionartificial-intelligencelife-sciencestherapeuticsskin-carepatientswomen-healthwellnessdrug-developmentconsumerspersonalizationbiotechnologybioconvergenceGeographic Markets
IsraelMyBiotics Pharma Financials
$11.27M
Total funding
Undisclosed
Capital raised
Undisclosed
Last funding
A
Funding stage
5
Total rounds
1
Investors
Cumulative Funding Raised Over Time ($)
$8.0MAug 2018
$8.0MFeb 2021
$8.7MMar 2016
$9.0MMay 2015
Private Equity Funding
Undisclosed Round
Feb 2021
Undisclosed
Maruho Israel Innovation Fund
A Round
Aug 2018
$8M
Seed
Mar 2016
$650K
Seed
May 2015
$320K
Non-Equity Funding
GrantEvent
Oct 2020
$2.3M
EU Horizon 2020
MyBiotics Pharma Lifecycle
Cumulative Funding Raised Over Time
$8.0MAug 2018
$8.0MFeb 2021
$8.7MMar 2016
$9.0MMay 2015
All Events
Undisclosed Round
Feb 2021
Undisclosed
Maruho Israel Innovation Fund
A Round
Aug 2018
$8M
Seed
Mar 2016
$650K
Seed
May 2015
$320K
GrantEvent
Oct 2020
$2.3M
EU Horizon 2020
MyBiotics Pharma News
9 articles
growth-positive
MyBiotics announces successful completion of the Phase I trial for its MBX-SD-202 whole microbiome treatment, driving an innovative path to new restoration therapies using microbiome culturing technology
MyBiotics Pharma Ltd has successfully completed Phase I clinical trial of MBX-SD-202, a whole microbiome treatment for recurrent and severe cases of Clostridioides difficile infection. The trial confirmed the safety of MBX-SD-202 in healthy volunteers and supports further development of the companys SuperDonor™ technology. MyBiotics plans to continue clinical development of MBX-SD-202 for recurrent C. diff and related medical indications. The SuperDonor™ technology has the potential to be applied to multiple indications, such as oncology, in the companys clinical pipeline. MyBiotics is a clinical stage company focused on microbiome-based products for the biopharmaceutical and supplement markets.
Customers
growth-positive
MyBiotics, Hadassah to study impact of microbiome on cancer therapies
MyBiotics Pharma Ltd. is partnering with Hadasit Medical Research Services and Development Ltd., the technology transfer arm of Hadassah Medical Center, to develop microbiome-based therapies to improve cancer immunotherapies for melanoma patients. MyBiotics has developed technologies to culture, ferment, and deliver stable and diverse bacterial communities that can target different sites across the human body to restore the microbiome equilibrium. The collaboration will combine Hadassah’s expertise in immunotherapy treatment for melanoma patients with MyBiotics’ microbiome technologies.
Partners
growth-positive
Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health BioSpace
Ferring Pharmaceuticals, Rebiotix Inc., and MyBiotics Pharma Ltd. have announced a strategic collaboration to develop live microbiota-based biotherapeutics for bacterial vaginosis. The collaboration aims to reduce the need for antibiotics and provide a long-term treatment solution for the common vaginal infection. The agreement combines MyBiotics culturing and delivery technologies with Rebiotixs expertise in developing clinical-stage microbiota-based products and Ferrings therapeutic development and commercial expertise. The collaboration is an important step forward in harnessing the power of the human microbiome in womens health. The partnership between Ferring and MyBiotics builds on their existing collaboration initiated in 2017. The collaboration also adds several firsts to Ferrings microbiome product pipeline, including the companys first non-donor derived formulation and a live microbiota-based product specific to reproductive medicine.
Partners
growth-positive
MyBiotics Pharma Receives Investment from Mii Fund, an Innovator in the Field of Dermatology
MyBiotics Pharma has received an investment from Mii Fund, a partnership with Maruho Co. Ltd., to advance its microbiome therapeutics pipeline and enhance its microbiome platform technologies. The company is also initiating a development program in the field of skin microbiome. MyBiotics has developed breakthrough technologies for generating a stable and diverse bacterial community. The investment will strengthen the companys technology platforms and accelerate the development of its microbiome-based pipeline.
InvestmentPartners
growth-positive
Galmed and MyBiotics to Collaborate in Development of Bespoke Microbiome Signature for Aramchol
Galmed Pharmaceuticals and MyBiotics Pharma have entered into a research and development collaboration agreement to identify and optimize the selected microbiome repertoire associated with the response to Aramchol. The collaboration aims to develop a standalone microbiome-based treatment for non-alcoholic steatohepatitis (NASH) and fibrosis. MyBiotics will use its proprietary SuperDonor technology to identify and optimize consortia of bacteria to enhance Aramchols clinical efficacy and response rate. The collaboration also aims to identify specific microbial biomarkers for Aramchol based on macrobiome data collected from Galmeds clinical studies. The partnership is part of Galmeds plan to maximize Aramchols clinical efficacy and leverage the growing interest in the microbiome as a novel drug modality.
Partners
growth-positive
Going on a gut feeling: Horizon 2020 grants $2.3M to Israel-based MyBiotics
Israeli life-science firm MyBiotics Pharma Ltd. has been awarded a $2.3 million grant by the European Union as part of its Horizon 2020 Program. MyBiotics develops microbiome-based therapeutics solutions, including multi-strain collections of human bacteria for the generation of personalized, human-bacteria based probiotics. The grant will support the development of a novel technology enabling efficient delivery of personalized probiotics to prevent gut-related diseases and recover damaged gut microbiota.
Investment
growth-positive
Ferring looks to Israel for innovative biotech
The article discusses the growth of Swiss pharmaceutical company Ferring, which has achieved annual revenue of $2 billion through improving the user experience of older products. The companys big breakthrough was not based on a bestselling drug, but rather on upgrading existing products. Ferring acquired Israeli biotechnology pioneer Bio-Technology General (BTG) and integrated it into the company. Ferring focuses on fertility, urology, and gastroenterology, and has recently made an acquisition in the microbiome field. The company is also considering entering the cancer field. The article emphasizes the importance of patient experience and the potential impact of microbiome products on various diseases. Ferring is a private family company that operates in many countries and treats its employees well.
InvestmentAcquisition
growth-positive
Making good bacteria more resilient
Israeli microbiome company MyBiotics Pharma has signed an option to license agreement with Ferring Holding for the use of MyCrobe technology in womens health. The technology aims to make good bacteria more resilient and potent. MyBiotics plans to develop a product to treat Clostridium difficile without implanting feces.
Partners
growth-positive
MyBiotics signs second option agreement with Ferring Holding for the validation
MyBiotics Pharma has entered into a second option agreement with Ferring Holding Ltd. for the validation of its microbiome-based therapeutics in the field of womens health. MyBiotics has developed breakthrough production and fermentation techniques for growing a stable and diverse bacterial community that can restore microbiome equilibrium. The partnership with Ferring Group has the potential to lead to novel treatments in the fields of gastroenterology and womens health.
Partners
MyBiotics Pharma Team
Employee Info
| Employees (range) | 11-50 |
| Exact count | 13 |
| Team members | 4 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 15 classification IDs that could be used for matching.
MyBiotics Pharma Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 100/100 |
| BI Verification | Jenny Sotnik-Talisman |
| Registrar ID | 515094514 |
| Crunchbase | mybiotics-pharma |
| Phone | +97286347647 |
| Creator | Sharon Shapira |
| Creator email | shapira.sharon2@gmail.com |
| Last updater | Yanina Wainscheinker |
| Updater email | yanina.wainscheinker@sncentral.org |
| Last update | 2022-11-11T00:00:00.000Z |
| Created | 2015-05-03T00:00:00.000Z |
| Claimed | Yes |